Analytical Data
-
Gene name
SLC2A9
- Application
-
Alternative Names
(Glucose transporter type 9)(GLUT-9)(Urate transporter)
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NRM0
-
Expression Region
1-540aa
-
Molecular Weight
60.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC2A9, a member of the solute carrier family 2, is primarily responsible for the transport of urate across cell membranes, playing a crucial role in uric acid homeostasis and related diseases. Dysregulation of SLC2A9 has been associated with hyperuricemia, gout, and even kidney disorders, making it a significant target for therapeutic intervention. The study of SLC2A9 recombinant proteins offers valuable insights into its structural and functional properties, which can facilitate the development of selective inhibitors or activators for clinical use. By expressing and purifying SLC2A9 in a heterologous system, researchers can conduct various biochemical assays to understand the transport mechanisms and substrate specificity better. Furthermore, the creation of mutants or tagged versions of SLC2A9 aids in elucidating its interaction with various regulatory proteins and small molecules. Consequently, advances in recombinant SLC2A9 studies could lead to innovative strategies for managing conditions related to urate transport and metabolism, thereby contributing to improved health outcomes for patients with hyperuricemia and gout-related disorders.
